R. B. Free, Ph.D.
Affiliations: | 2002 | Ohio State University, Columbus, Columbus, OH |
Area:
Pharmacology, Neuroscience BiologyGoogle:
"R. Free"Mean distance: 35622
Parents
Sign in to add mentor| Dennis B. McKay | grad student | 2002 | Ohio State | |
| (Characterization and regulation of adrenal neuronal nicotinic acetylcholine receptors.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Free RB, Cuoco CA, Xie B, et al. (2021) Pharmacological characterization of the imipridone anti-cancer drug ONC201 reveals a negative allosteric mechanism of action at the D dopamine receptor. Molecular Pharmacology |
| Moritz AE, Bonifazi A, Guerrero AM, et al. (2020) Evidence for a stereoselective mechanism for bitopic activity by extended-length antagonists of the D3 dopamine receptor. Acs Chemical Neuroscience |
| Schardien KA, Soto MS, Inbody L, et al. (2020) Investigation of G protein‐coupled receptor kinase 2 (GRK2) regulation of D 2 dopamine receptor signaling: effects of GRK2 functional domains and pharmacologic and genetic inhibition of GRK2 activity The Faseb Journal. 34: 1-1 |
| Sanchez-Soto M, Schardien KA, Inbody L, et al. (2020) G protein‐coupled receptor kinase 2 can enhance beta‐arrestin recruitment to the D 2 dopamine receptor in the absence of receptor phosphorylation The Faseb Journal. 34: 1-1 |
| Moritz AE, Inbody LR, Gandhi DM, et al. (2020) Structure‐Activity Relationships of a Negative Allosteric Modulator of the D3 Dopamine Receptor and Investigation of its Binding Site The Faseb Journal. 34: 1-1 |
| Keck TM, Free RB, Day MM, et al. (2019) Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy. Journal of Medicinal Chemistry |
| Luderman KD, Conroy JL, Free RB, et al. (2018) Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites. Molecular Pharmacology |
| Madhukar N, Prabhu VV, Anantharaman L, et al. (2017) EXTH-43. DIFFERENTIATED PHARMACOLOGY OF THE IMIPRIDONE ONC201, THE FIRST SELECTIVE DRD2/3 ANTAGONIST IN CLINICAL NEURO-ONCOLOGY Neuro-Oncology. 19: vi81-vi82 |
| Michino M, Free RB, Doyle TB, et al. (2015) Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors. Chemical Communications (Cambridge, England). 51: 8618-21 |
| Meade JA, Free RB, Miller NR, et al. (2015) (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling. Psychopharmacology. 232: 917-30 |